MTOR and Hyperglycemia: Although the appealing prospects of simultaneously targeting PI3K/mTOR, clinical studies have revealed a limited efficacy and important toxicity concerns (e.g., nausea, diarrhea, vomiting, decreased appetite, hyperglycemia, mucositis, cutaneous rash, elevated liver enzyme levels, renal failure, and hypertension).